Status:
UNKNOWN
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute
Conditions:
Major Depression
Pain
Eligibility:
All Genders
18-64 years
Phase:
PHASE4
Brief Summary
Patients with major depressive disorder (MDD) commonly have many gastrointestinal complaints. Gastrointestinal pain is classified into 2 categories: visceral and somatic pain. The main aim of this stu...
Eligibility Criteria
Inclusion
- MDD according with DSM-IV-TR
- Hamilton depression scale \> 21
Exclusion
- history of gastrointestinal illness
- history of escitalopram, citalopram or reboxetine allergy.
- history of escitalopram, citalopram or reboxetine resistant depression.
- other axis I psychiatric disorder.
- a punctuation \> 2 on the suicide item of the Ham-D.
- history of ECT during the past 6 months.
- pharmacological failure of the present depressive episode.
- pregnancy or nursing.
- treatment with drugs that may interact with study medication.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2011
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00209807
Start Date
September 1 2005
End Date
April 1 2011
Last Update
May 27 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitari vall d'Hebron
Barcelona, Catalonia, Spain, 08036